ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

http://oncologypro.esmo.org/Meeting-Resourc...r-malignant-extrahepatic-bile-duct-stricture

Pathologic confirmation is very important in patients with malignant bile duct strictures irrespective of operability. The numerous studies of diagnostic methods for malignant bile duct strictures...

Date: 28 Jun 2017
Presenter: Ju-Il Yang
Resources: Abstract
Topics: Gastrointestinal Cancers, Hepatobiliary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...ma-HCC-who-progressed-on-sorafenib-treatment

The phase 3 RESORCE trial showed that regorafenib improved the primary endpoint of OS versus placebo in patients with unresectable HCC who progressed during sorafenib treatment.

Date: 28 Jun 2017
Presenter: Merle Philippe
Resources: Abstract
Topics: Gastrointestinal Cancers, Hepatobiliary Cancers

http://oncologypro.esmo.org/Meeting-Resourc...lic-mutant-metastatic-colorectal-cancer-mCRC

BEAMing was performed in plasma samples from a total of 110 patients with mCRC from different institutions. The technique provides MAF quantification with a sensitivity of 0.01%.

Date: 28 Jun 2017
Presenter: Sanz-García Enrique
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...in-patients-treated-for-colorectal-carcinoma

Peripheral neuropathy secondary to oxaliplatin is very frequent it is defined by damage of the peripheral nervous system generated by oxaliplatin, due to the fragility of the blood-brain barrier in the peripheral nerve.

Date: 28 Jun 2017
Presenter: Soumeyya Ghomari-Bezzar
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

http://oncologypro.esmo.org/Meeting-Resourc...t-in-patients-with-resectable-gastric-cancer

In several European countries it is recommended to treat gastric cancer patients with perioperative chemotherapy if they are eligible for surgery. However, little is known about its use in daily clinical practice.

Date: 28 Jun 2017
Presenter: Valery Lemmens
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

http://oncologypro.esmo.org/Meeting-Resourc...subtype-of-metastatic-colorectal-cancer-mCRC

RET fusions occur in less than 1% of CRCs, and may represent new therapeutic targets, as indicated by earlier promising reports of individual patients treated with tyrosine kinase inhibitors.

Date: 28 Jun 2017
Presenter: Alexa Schrock
Resources: Abstract
Topic: Gastrointestinal Cancers

http://oncologypro.esmo.org/Meeting-Resourc...factors-of-gastric-adenocarcinoma-in-Tunisia

Gastric cancer is the second most common cause of death from cancer worldwide. Few data are available on its epidemiology and outcome in Tunisia. We aimed in this study to reports epidemiological,...

Date: 28 Jun 2017
Presenter: Haifa Rachdi
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

http://oncologypro.esmo.org/Meeting-Resourc...eropancreatic-neuroendocrine-tumors-GEP-NETs

Antiproliferative efficacy of SA in midgut NETs was proved in PROMID study. But this study included patients only with G1 tumors. We assessed efficacy of the SA in pts with metastatic (advanced) G1 and...

Date: 28 Jun 2017
Presenter: Nadezhda Orel
Resources: Abstract
Topic: Neuroendocrine Cancers

http://oncologypro.esmo.org/Meeting-Resourc...astric-cancer-patients-with-brain-metastasis

Introduction: Brain metastases from gastric cancer is exceedingly rare. This study sought to analyze the clinical features of gastric cancer and brain metastasis and prognostic factors for patient survival.

Date: 28 Jun 2017
Presenter: Joohan Lim
Resources: Abstract
Topics: Gastrointestinal Cancers, Gastric Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ment-in-esophageal-cancer-in-the-Netherlands

Treatment for esophageal cancer has evolved due to developments including the introduction of neoadjuvant chemoradiotherapy and centralization of surgery. This study evaluated trends in stage distribution,...

Date: 28 Jun 2017
Presenter: Margreet van Putten
Resources: Abstract
Topics: Gastrointestinal Cancers, Oesophageal Cancer